Supplementary Table S1 Classification of patients according to clinical risk assessment by the mAOL

ER status	HER2 status	Grade	Nodal status	Tumor size	Clinical risk in MINDACT trial
ER positive	HER2 negative	Well differentiated	N-	≤ 3 cm	C-low
				3.1–5 cm	C-high
			1–3 positive nodes	≤ 2 cm	C-low
				2.1–5 cm	C-high
		Moderately differentiated	N-	≤ 2 cm	C-low
				2.1–5 cm	C-high
			1–3 positive nodes	Any size	C-high
		Poorly differentiated OR Undifferentiated	N-	≤ 1 cm	C-low
				1.1–5 cm	C-high
			1–3 positive nodes	Any size	C-high
	HER2 positive	Well differentiated OR Moderately differentiated	N-	≤ 2 cm	C-low
				2.1–5 cm	C-high
			1–3 positive nodes	Any size	C-high
		Poorly differentiated OR Undifferentiated	N-	≤ 1 cm	C-low
				1.1–5 cm	C-high
			1–3 positive nodes	Any size	C-high
ER negative	HER2 negative	Well differentiated	N-	≤ 2 cm	C-low
				2.1–5 cm	C-high
			1–3 positive nodes	Any size	C-high
		Moderately differentiated OR Poorly differentiated OR Undifferentiated	N-	≤ 1 cm	C-low
				1.1–5 cm	C-high
			1–3 positive nodes	Any size	C-high
	HER2 positive	Well differentiated OR Moderately differentiated	N-	≤ 1 cm	C-low
				1.1–5 cm	C-high
			1–3 positive nodes	Any size	C-high
		Poorly differentiated OR Undifferentiated	Any	Any size	C-high

Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; mAOL, modified Adjuvant Online.
Note: In this study, C-high and C-low are indicated simply as high and low, respectively.